Skip to main content

Advertisement

Table 3 Changes in optical coherence tomography measurements by treatment group

From: Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series

  Ranibizumab-aflibercept-ranibizumab treatment group (N = 10) Wilcoxon p value Friedman’s p value Ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab treatment group (N = 9) Wilcoxon p value Friedman’s p value
  Median (interquartile range) Median (interquartile range)   
Central macular thickness (CMT), μm 0.002   0.001
 OCT 1 335.5 (308.25–381.75) 283 (252.5–382.5)  
 OCT 2 302.5 (222–360.75) 0.030a 285 (220.5–442.5) 0.38a
 OCT 3 375 (292.75–435.25) 0.016b 295 (216.5–392.5) 0.22b
 OCT 4 314 (232.5–399.75) 0.021c 248 (212.5–333.5) 0.037c
Total Fluid Volumed, mm3 0.007   0.003
 OCT 1 3.50 (2.47–5.52) 1.68 (0.71–5.28)  
 OCT 2 3.55 (1.49–4.73) 0.121a 1.36 (0.58–4.20) 0.221a
 OCT 3 4.28 (2.94–6.27) 0.018b 0.96 (0.76–3.85) 0.297b
 OCT 4 2.87 (2.31–4.31) 0.024c 0.77 (0.47–2.72) 0.087c
Subretinal fluid (SRF), mm3 0.007   0.003
 OCT 1 0.11 (0.013–1.12) 0.16 (0.003–0.82)  
 OCT 2 0.15 (0–0.76) 0.091a 0.11 (0.006–0.59) 0.077a
 OCT 3 0.68 (0.01–1.68) 0.178b 0.33 (0.04–1.15) 0.077b
 OCT 4 0.06 (0–0.40) 0.004c 0.09 (0.008–0.31) 0.038c
Intraretinal fluid (IRF), mm3 0.003   0.010
 OCT 1 0.04 (0–1.74) 0 (0–0.73)
 OCT 2 0.008 (0–0.07) 0.032a 0.0002 (0–0.49) 0.426a
 OCT 3 0.22 (0.0006–0.96) 0.012b 0 (0–0.59) 0.335b
 OCT 4 0.0009 (0–0.99) 0.206c 0 (0–0.44) 0.377c
Pigment Epithelial Detachment (PED), mm3 0.0003   0.003
 OCT 1 2.39 (1.77–3.23) 0.67 (0.18–3.85)
 OCT 2 2.36 (1.35–4.38) 0.222a 0.83 (0.20–3.40) 0.430a
 OCT 3 2.49 (1.90–4.13) 0.070b 0.86 (0.18–2.63) 0.107b
 OCT 4 2.39 (2.05–3.23) 0.480c 0.50 (0.16–2.03) 0.187c
  1. Treatment response of chronic neovascular age-related macular degeneration patients by treatment group: ranibizumab-aflibercept-ranibizumab vs. ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab
  2. Patients were divided into three treatment groups: those patients who had received bevacizumab only, then aflibercept, and then bevacizumab again (bevacizumab-aflibercept-bevacizumab), those patients who had received ranibizumab only, then aflibercept, and then ranibizumab again (ranibizumab-aflibercept-ranibizumab), and those patients who had received all three medications over the course of their treatment (ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab). The bevacizumab-aflibercept-bevacizumab group contained only two patients and was thus excluded from further analysis
  3. aComparing response from bevacizumab or ranibizumab (OCT 1) to aflibercept (OCT 2)
  4. bComparing progression while on aflibercept (OCT 2 and OCT 3)
  5. cComparing response back to bevacizumab or ranibizumab (OCT 4) from aflibercept (OCT 3)
  6. dSummation of subretinal fluid, intraretinal fluid, and pigment epithelial detachments